Previous 10 | Next 10 |
Intec Pharma (NASDAQ: NTEC ): FY GAAP EPS of -$1.41 beats by $0.01 . More news on: Intec Pharma Ltd., Earnings news and commentary, Healthcare stocks news, , Read more ...
JERUSALEM , March 13, 2020 /PRNewswire/ -- Intec Pharma Ltd. (NASDAQ: NTEC) ("Intec" or "the Company") today announces financial results for the fourth quarter and year ended December 31, 2019 and provides a corporate update. Highlights from the Quarter and Recent Weeks De...
JERUSALEM , Feb. 25, 2020 /PRNewswire/ -- Intec Pharma Ltd. (NASDAQ: NTEC) ("Intec" or "the Company") today announces that Company management will participate at the following upcoming investment conferences in March. Cowen 40th Annual Health Care Conference Date:...
Intec Pharma (NASDAQ: NTEC ) has priced its public offering of 16.25M ordinary shares and warrants to purchase up to same number of ordinary shares at $0.40/share, for gross proceeds of $6.5M. More news on: Intec Pharma Ltd., Healthcare stocks news, , Read more ...
JERUSALEM, Jan. 30, 2020 (GLOBE NEWSWIRE) -- Intec Pharma Ltd. (NASDAQ: NTEC) ("Intec" or "the Company") today announced the pricing of its previously announced underwritten public offering of 16,250,000 ordinary shares (which includes pre-funded warrants to purchase ordinary shares in lieu...
Intec Pharma (NASDAQ: NTEC ) is down 20.3% on heavy after-hours volume following its announcement of a proposed public offering of ordinary shares and warrants. More news on: Intec Pharma Ltd., Healthcare stocks news, Stocks on the move, Read more ...
JERUSALEM , Jan. 30, 2020 /PRNewswire/ -- Intec Pharma Ltd. (NASDAQ: NTEC) ("Intec" or "the Company") today announced that it intends to offer and sell a combination of ordinary shares (or pre-funded warrants to purchase ordinary shares in lieu thereof) and warrants to purchase ordin...
JERUSALEM , Jan. 9, 2020 /PRNewswire/ -- Intec Pharma Ltd. (NASDAQ: NTEC) ("Intec" or "the Company") today provides a business and clinical update on its development programs with the Company's proprietary oral drug delivery system, the Accordion Pill ® platform, in a Letter to Sh...
The following slide deck was published by Intec Pharma Ltd. in conjunction with this Read more ...
JERUSALEM , Dec. 11, 2019 /PRNewswire/ -- Intec Pharma Ltd. (NASDAQ: NTEC) ("Intec" or "the Company") today announces the termination of the Feasibility and Option agreement with Novartis for the development of a custom-designed Accordion Pill ® (AP) for a proprietary Novartis co...
News, Short Squeeze, Breakout and More Instantly...
Intec Pharma Ltd. Company Name:
NTEC Stock Symbol:
NASDAQ Market:
- Chief Scientific Officer Dr. Newman to present initial clinical data that further validates Company’s “Pulse-Prime” hypothesis - Dr. Newman also named Chair of the Summit NEW YORK, June 11, 2024 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc, (Nasdaq: INDP), a...
NEW YORK, June 04, 2024 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc, (Nasdaq: INDP), a clinical stage biotechnology company dedicated to pioneering innovative cancer and viral infection treatments, today announced that its Chief Medical Officer, Roger Waltzman, M.D., will present an update on ...
Latest data from first and second cohorts support Company’s 'pulse-prime' approach, demonstrating rapid clearance, broad immune activation, and encouraging safety profile Poster Presented at American Society of Clinical Oncology Annual Meeting NEW YORK, June 03, 2024 (GLOBE...